FDA postpones panel for Glaxo’s COPD drug as snowstorm advances

(Reuters) – The Food and Drug Administration said on Tuesday it has postponed a meeting of outside advisers scheduled for March 7 to review a drug developed by GlaxoSmithKline Plc and Theravance Inc for chronic obstructive pulmonary disease (COPD). The agency did not officially give a reason for the postponement but it comes as a major snowstorm bears down on the Northeastern United States, including Washington D.C., where the panelists were due to meet. …